Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04124926 · ClinicalTrials.gov registry record · Phase 3
Efficacy and Safety of Vonoprazan Compared to Lansoprazole in Participants With Erosive Esophagitis
A Phase 3 study, sponsored by Phathom Pharmaceuticals.
- Completed
- Registry status
- Phase 3
- Development phase
- 1,027
- Enrollment target
NCT04124926: Completed Phase 3 study, sponsored by Phathom Pharmaceuticals.
NCT04124926 is a Phase 3 study that has completed, run by Phathom Pharmaceuticals. The registered enrollment target is 1,027 participants, above the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (33% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04124926, a Phase 3 study, has completed, sponsored by Phathom Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 1,027 participants
- Enrollment target
Study Summary
To evaluate the efficacy and safety of vonoprazan compared to lansoprazole in participants with erosive esophagitis.
Primary Outcome
A participant was considered to have complete healing of EE if healing was demonstrated during endoscopy.
Interventions
- DRUG Vonoprazan
- DRUG Lansoprazole
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,027 participants |
| Start Date | 2019-10-28 |
| Est. Completion | 2021-08-24 |
| Phase | Phase 3 |
What the finished NCT04124926 record still lists
NCT04124926 is an interventional study that assigns participants to a tested intervention. Its 1,027 participants enrollment target places it among the larger protocols in the corpus, above the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (33% higher).
The record links to 0 conditions, and to 2 interventions - of which Vonoprazan is the first listed.
NCT04124926 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT04124926 about?
NCT04124926 is a clinical study titled "Efficacy and Safety of Vonoprazan Compared to Lansoprazole in Participants With Erosive Esophagitis". To evaluate the efficacy and safety of vonoprazan compared to lansoprazole in participants with erosive esophagitis.
What is the current status of trial NCT04124926?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 1,027 participants. The study started on 2019-10-28. Estimated completion is 2021-08-24.
What interventions are being tested in trial NCT04124926?
The interventions under investigation include: Vonoprazan (DRUG), Lansoprazole (DRUG).
Who is sponsoring clinical trial NCT04124926?
This trial is sponsored by Phathom Pharmaceuticals, which has 13 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT04124926's enrollment target sits among peer trials
1,027 288th of 2000 higher than 1,713 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02200276 · 1,025 participants · NA
Influenza Immunization in Adults Over Age 75
- NCT02296450 · 1,025 participants
Quality of Life (QoL) Assessment in Cancer Patients and Survivors With Dermatologic Conditions Using Dermatologic QoL Instruments
- NCT06080698 · 1,030 participants · NA
Gram-Negative Bloodstream Infection Oral Antibiotic Therapy Trial
- NCT06888011 · 1,024 participants · NA
iAmHealthy Clinical Practice Guideline (CPG)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI